Gilead announced long-acting HIV-1 capsid inhibitor, lenacapavir, achieved primary endpoint in phase 2/3 study
On Nov. 18, 2020, Gilead Sciences announced topline results from the Phase 2/3 CAPELLA trial evaluating the company’s…
On Nov. 18, 2020, Gilead Sciences announced topline results from the Phase 2/3 CAPELLA trial evaluating the company’s…
On Sept. 30, 2020, the National Institutes of Health (NIH) announced funding of a nationwide study to discover…
On Aug. 3, 2020, Atossa Therapeutics announced that it had received approval from the ethics committee to open…
On Apr. 6, 2020, the National Cancer Institute awarded of $14.54 million to Roswell Park Comprehensive Cancer Center…
On Nov. 27, 2018, the Canadian Cancer Trials Group, a new clinical trial, opened across Canada. This was…
On Aug. 29, 2016, Scripps Health and MD Anderson Cancer Center announced a partnership agreement to create Scripps…
On Sept. 24, 2009, the second Phase III HIV-1 vaccine trial, also known as RV144, that began in…
On Jul. 22, 1993, revising a policy from 1977 that excluded women of childbearing potential from early drug…
In 1993, the Prostate, Lung, Colorectal, and Ovarian trial was launched. The trial was designed to determine whether…
In 1992, the National Cancer Institute (NCI) awarded the Pacific Health Research Institute its largest and most enduring…
In 1991, the American Association of Clinical Endocrinologists (AACE) was founded by a visionary group of leaders to…
On Jun. 25, 1988, the U.S. Postal Service (USPS) proposed to ban mailings of microbe samples capable of…
In 1988, the U.S. Food and Drug Administration (FDA) published a final rule, Annual Summary Reporting Requirements Under the…
In 1974, ground was broken on The Scripps Clinic and Research Foundation’s new site on the Torrey Pines…
In 1974, Albert Einstein Cancer Center’s Liver Research Center — now the interdisciplinary Marion Bessin Liver Research Center…
In 1973, the Ohio State University Cancer Center (OSUCCC) was established in Columbus. The patient care arm of…